Note: Descriptions are shown in the official language in which they were submitted.
4~
-- 1 --
Title of the Invention
ANTI-HUMAN MESOTHELIAL CELL
MONOCLONAL ANTIBODY
BACKGROUND OF THE INVENTION
. _
The present invention relates to a monoclonal
antibody capable of specifically reacting with the human
mesothelial cell and to a method of producing the monoclonal
antibody. The present invention is useful in diagnosis of
cancers such as cytological diagnosis of expectoration for
lung cancer, cytological diagnosis of pleural effusion for
lung cancer and cytological diagnosis of ascitic fluid for
various abdominal cancers.
It is known that in lung cancer, cancer cells
desquamate into sputum and/or pleural effusion, and that in
various abdominal cancers, cancer cells desquamate into
ascitic fluid. Therefore, it is important in diagnosis of
cancer to detect cancer cells desquamating into sputum and/or
pleural effusion, or ascitic fluid. Diagnosis and
differentiation of cancer cells are generally carried out by
pathologists. Sputum, pleural effusion and ascitic fluid
contain many kinds of normal cells, and above all it is
difficult to distinguish cancer cells from mesothelial cells
and macrophages.
Recently, many monoclonal antibodies having
specificity for cancer cells have been produced by hybridoma
technique, and application of the monoclonal antibodies to
cytodiagnosis have been made. Since some of the monoclonal
antibodies react with macrophages and/or mesothelial cells or
some of them react only with particular cancer cells, it is
not easy to carry out cytodiagnosis of cancer by use of the
monoclonal antibodies. Especially, it is difficult for even a
pathologist to distinguish cancer cells from mesothelial
cells.
Accordingly, a monoclonal antibody which
specifically reacts with the mesothelial cell but not with
cancer cells, if available, would be useful in the
cytodiagnosis of cancer. No monoclonal antibodies and
antisera being capable of specifically reacting with the
mesothelial cell have been known so far.
The present inventors have first produced hybridomas
between spleen cells of a mouse immunized with human
mesothelial cells and murine myeloma cells and selected a
hybridoma producing a monoclonal antibody which is capable of
specifically reacting with human mesothelial cells but not
with various human cancer cells. Further, the present
inventors have made cytological diagnosis of expectoration,
pleural effusion and ascitic fluid from patients with cancer
using the monoclonal antibody produced by the hybridoma and
found that the monoclonal antibody of the present invention
has a great significance in clinical pathology, and have now
completed the present invention.
SUMMARY OF THE INVENTION
The present invention provides a monoclonal antibody
of the IgG class capable of specifically reacting with human
mesothelial cells but not with other normal human cells and
human tumor cells.
DESCRIPTION OF THE INVENTION
The monoclonal antibody according to the present
invention is obtained by fusing spleen cells of a mouse
immunized with human mesothelial cells, with murine myeloma
cells to prepare hybridomas, selecting from among the
resulting hybridomas a hybridoma clone producing the required
monoclonal antibody, and cultivating the selected hybridoma in
a suitable culture medium or intraperitoneally administering
the selected hybridoma to a mouse thereby to cause hybridoma
1~4~'~.5
-- 3
cell propagation in the ascitic fluid in the mouse, followed
by separation of the product antibody from the culture medium
or the ascitic fluid as the case rnay be.
A method of producing the monoclonal antibodies
according to the invention is described in detail below.
(1) Immunization of animal and preparation of antibody-
producing cells
Mice between 3-10 weeks of age, preferably 8-week-
old mice, are immunized with human mesothelial cells, to cause
such mice to prepare antibody-producing cells in the spleen,
lymph node and peripheral blood. The immunization is
performed generally by administering human mesothelial cells
(5x105 to 5X106 cells per animal), together with an
appropriate adjuvant (e.g. Freund's complete adjuvant, or
aluminum hydroxide gel plus B. pertussis vaccine) to the mice
subcutaneously, intravenously or intraperitoneally.
Thereafter, the same antigen administration is repeated 2 to 5
times at 1 to 2 week intervals. Three to seven days after
each immunization, the blood is sampled from the eyeground
venous plexus and the serum of each sample is tested to
determine whether it reacts with human mesothelial cells by
the immunocytochemical staining given hereinafter.
Immunocytochemical staining:
A mesothelial cell suspension (lx107 cells/mQ) in
PBS comprising 1.83 g of disodium phosphate, 0.21 g of
monopotassium phosphate and 7.65 g of sodium chloride in 1 Q
of distilled water (pH 7.2) is distributed into the wells of a
12-well micro-titer slide glass (Flow Laboratories, CAT No.
60-412-05) coated with egg white albumin in an amount of 5 ~Q
per well and dried over cooled air for 5 to 10 minutes.
Then, acetone cooled at -20 to -30C is added to
each well and the slide glass is allowed to stand for 10
minutes. After drying for 2 to 3 minutes, endogenous
peroxidase is inactivated by immersion in 3~ hydrogen peroxide
in methanol solution for 30 minutes. After washing well with
4~,2~
-- 4
PBS, 20 ~Q of antiserum or monoclonal antibody solution (1 to
20 ~g/mQ) is distributed into each well as the first antibody,
and the slide glass is allowed to stand for 30 minutes to 2
hours at room temperature and washed well with PBS. Then,
20 ~Q of a biotin-labeled rabbit anti-mouse immunoglobulin
(10 ~g/mQ) is distributed into each well as the second
antibody, and the glass is allowed to stand at room
temperature for 30 minutes and then washed well with PBS.
Avidin-biotin-peroxidase complex (ABC reagent, product of
Vector) is added to the wells, and the glass is allowed to
stand at room temperature for 30 minutes and then washed well
with PBS. Color is developed by the addition of
diaminobenzidine as the substrate solution for peroxidase, and
the glass is observed with a microscope.
The procedure subsequent to ABC reagent is made by
the method recommended by Vector. When the target cell is
various tumor cells or normal cells instead of mesothelial
cells, the immunocytochemical staining is conducted in the
same manner except for changing a cell fixed on a slide glass
as the first step. In preparation for cell fusion, human
mesothelial cells are intraperitoneally administered to the
immunized mice in a dose of 5x105 to 5X106 cells per animal 3
to 4 days prior to the fusion treatment. The spleens are then
extirpated and the spleen cells are prepared for fusion.
That is, the spleen is cut into fragments in MEM
(product of Nissui Pharmaceutical), loosened up with forceps,
and centrifuged at 1,200 rpm for 5 minutes. The supernatant
is discarded, and the sediment are deprived of erythrocytes by
treatment with Tris-ammonium chloride buffer (pH 7.65) for 1-2
minuies, washed three tlmes with MEM, and used as the spleen
cells for fusion.
Mesothelial cells are obtained from intine of thorax
and of abdominal cavity on autopsies. Cells are collected
from the surface of the intine and washed with PBS two or
three times. Alternatively, mesothelial cells are obtained
-- 5 --
from the homogenates of the cardiac vesicle are washed with
PBS and centrifuged at 1,200 rpm for 5 minutes, and then the
pellet is suspended in PBS.
(2) Preparation of myeloma cells
A mouse-derived established myeloma cell line is
used. Suitable examples are the 8-azaguanine resistant mouse
(BALB/c-derived) myeloma cell lines P3-X63Ag8-Ul (P3-Ul)
[Current Topics in Microbiology and Immunology 81, 1-7
(1978)], P3-NSI/l-Ag41 (NS-l) [European J. Immunology, 6, 511-
519 (1976)], SP2/0-Agl4 (SP-2) [Nature, 276, 269-270 (1978)],
P3-X63-Ag8 653 (653) [J. Immunology, 123, 1548-1550 (1979)]
and P3-X63-Ag8 (X63) [Nature, 256, 495-497 (1975)], all of
which are commercially available. The passage of these cell
lines is performed in 8-azaguanine medium [normal medium
prepared by adding, to RPMI-1640 medium, glutamine (1.5 mM),
2-mercaptoethanol (5x10-5 M), gentamicin (10 ~g/mQ) and fetal
calf serum (FCS; product of CSL) (10~), with further
supplementation with 8-azaguanine (15 ~g/mQ)]. The cell line
selected for cell fusion should be transferred to normal
medium 3 to 4 days before fusion to ensure the cell count of
not less than 2x107 on the day of fusion.
(3) Cell fusion
The antibody-producing cells immunized in (1) and
the myeloma cells obtained in (2) are washed well with MEM or
PBS and mixed in a cell number ratio of antibody-producing
cells : myeloma cells in the range of 5:1 to 10:1 and then
subjected to centrifugation (1,200 rpm, 5 minutes). The
supernatant is discarded and the cell sediment is loosened up.
With stirring at 37C, a mixture of 2 9 of polyethylene glycol
1,000 (PEG-l,000), 2 mQ of MEM and 0.7 mQ of dimethylsulfoxide
is added in an amount of 0.2-1 mQ per 103 antibody-producing
cells, and MEM is added until the whole volume is made 50 mQ
after several additions of 1-2 mQ of MEM at 1 to 2 minute
intervals. After centrifugation (900 rpm, 5 minutes), the
supernatant is discarded and the cell sediment is loosened
-- 6
gently. To the cells is added 100 mQ of normal medium (RPMI-
1640 with 10% FCS). The cells are gently suspended in the
medium with a measuring pipette.
The suspension obtained is distributed, in 1 mQ-
portions, into the wells of a 24-well incubation plate.
Incubation is carried out in a 5% C2 incubator at 37C for 24
hours. HAT medium [normal medium supplemented with
hypoxanthine (10-4 M), thymidine (1.5x10-5 M) and aminopterine
(4x10-7 M)] is added to the incubation plate (1 mQ per well)
and incubation is conducted for a further 24 hours.
Thereafter, 1 mQ of the culture supernatant is discarded and
the same volume of fresh HAT medium is added at 24-hour
intervals for 2 days. The incubation in the CO2 incubator at
37C is continued for 10-14 days.
In those wells in which grown fused colony-forming
cells are found, 1 mQ of the supernatant is discarded and the
same volume of HT medium (HAT medium minus aminopterine) is
added, followed by medium replacement with fresh portions of
HT medium at 24-hour intervals for 2 days.
After 3 to 4 days of cultivation in HT medium, a
portion of the culture supernatant is collected and assayed
for antibody titer relative to human mesothelial cells by the
above-mentioned immunocytochemical staining. In like manner,
the reactivities with normal human cells or tumor cells are
also determined, and those wells in which selective reactivity
with human mesothelial cells are selected.
Cloning is repeated twice by limiting dilution
technique and those clones for which high antibody titer value
are stably obtainable relative to human mesothelial cells, are
selected as anti-human mesothelial cell monoclonal antibody-
producing hybridoma cell lines.
(4) Preparation of monoclonal antibody
Eight- to ten-week-old female BALB/c mice treated
with pristane [intraperitoneally administered with 0.5 mQ of
2, 6, 10, 14-tetramethylpentadecane (pristane) and fed for 2-
4~
7 --
weeks] are intraperitoneally injected with the anti-human
mesothelial cell monoclonal antibody-producing hybridoma cells
obtained in procedure (3) above at a dose of 2-4x106 cells per
animal. In 10-21 days, the hybridoma cells produce ascites
carcinoma in the mice. The ascitic fluid is collected from
such mice, centrifuged (3,000 rpm, 5 minutes) to remove
solids, subjected to salting out with 50% ammonium sulfate,
dialyzed against 0.04 M phosphate buffer (~H 8.0) supplemented
with 0.03 M NaCl, and passed through DE52 ~ (product of
Whatman) column. An IgG fraction is collected and used as a
purified monoclonal antibody.
The isotype of the antibody is determined by
Ouchterlony's method (double immunodiffusion) [Seibutsukagaku
Jikkenho (Methods in Experimental Biochemistry), vol. 15,
Introduction to Experimental Immunology, p. 74, Gakkai Shuppan
Center, 1981].
The quantity of protein is estimated by the Folin's
method, followed by calculation based on the absorbance at
280 nm [1.4 (OD280) approximately corresponds to 1 mg of
immunoglobulin per mQ].
The monoclonal antibody thus obtained is effective
in cytological diagnosis of expectoration for lung cancer and
cytological diagnosis of pleural effusion for lung cancer and
cytological diagnosis of ascitic fluid for various abdominal
cancers by the above-mentioned immunocytochemical staining.
Certain specific embodiments of the present
invention are illustrated by the following examples.
Example 1
(1) Preparation of antibody-producing cells
Eight-week old female BALB/c mice (Shizuoka
Agricultural Cooperative Association for Laboratory Animals)
were intraperitoneally administered and immunised with human
mesothelial cells (2x106 cells per animal) as an antigen,
together with aluminium hydroxide gel (2 mg per animal) and
4~
killed B. pertussis vaccine (Chiba Serum Institute; lx109
cells per animal) as an adjuvant. The same antigen
administration was repeated 3-5 times at a dose of 2X106 cells
per animal at 1 to 2 week intervals without an adjuvant. From
among these immunized mice, those mice whose antisera
intensely reacted with human mesothelial cells were selected,
and spleen cells were prepared from such mice and submitted to
cell fusion.
(2) Preparation of myeloma cells
The 8-azaguanine-resistant murine myeloma cell line
P3-Ul was cultivated in normal medium to thereby secure not
less than 2x107 cells at the time of cell fusion, and
submitted to cell fusion as a parent strain.
(3) Hybridoma production
The spleen cells and myeloma cells obtained in (1)
and (2), respectively, were used in a ratio of 5:1 and
subjected to fusion according to the procedure previously
described. After cultivation in HAT medium at 37C in 5~ CO2
incubator for 14 days, fused cells were selected, and after
change of the medium to HT medium, cultivation was continued.
Based on the results of anti-human mesothelial cell antibody
titer determination, active wells were selected, and after
change of the medium to normal medium, cloning was repeated
twice by the limiting dilution technique. The clone for which
antibody titer value was stably obtainable relative to human
mesothelial cells was selected as anti-human mesothelial cell-
producing hybridoma cell line KM-277. The hybridoma cell line
KM-277 has been deposited with the European Collection of
Animal Cell Cultures, Great Britain, as of October 23, 1986 as
ECACC No. 86102303 under the Budapest Treaty.
(4) Monoclonal antibody purification
Eight-week-old female BALB/c mice treated with
pristane were intraperitoneally injected with the hybridoma
cell line KM-277 obtained in (3) at a dose of 4X106 cells per
animal. In 10-21 days, the hybridoma produced ascites
1~4~j~5
carcinoma. The ascitic fluid was collected from ascitic
fluid-bearing mice (5 to 10 mQ per animal), centrifuged to
remove solids (3,000 rpm, 5 minutes), subjected to salting out
with 40% ammonium sulfate, dialyzed against 0.04 M phosphate
buffer supplemented with NaCl (0.03 M), and passed through a
DE52 ~ (product of Whatman) column (bed volume: 50 mQ) at a
flow rate of 20 to 30 mQ/hr. An IgG fraction was collected
and used as the purified antibody.
(5) Antigenic specificity of KM-277
The specificity of the thus-obtained monoclonal
antibody KM-277 for three human mesothelial cell samples, two
human peripheral lymphocyte cell (PsL) samples and various
cancer cell lines was investigated using immunocytochemical
staining.
The results are shown in Table 1.
1~34~i~.5
-- 10 --
Table 1
Staining level by
Sample or Cell line KM-277*
Mesothelial cell sample A ++
B +
C ++
PBL sample A
B +
Myeloma cell line SK-Ly-18
T cell leukemia cell lines HSB-2
MOLT-3
Lung cancer cell line PC-10
PC- 7
PC-13
PC- 6
Gastric cancer cell line MKN-l
KATO-III - .
Pancreatic cancer cell line HPAF
Malignant melanoma cell line SK-28
Fetal lung cell line L-132
Fetal skin cell line Detroit 551
*Staining level observed with microscope.
4~i~5
As shown in Table 1, KM-277 was very specifieally
reactive with the human mesothelial cell but not with PBL and
the various cancer cell lines.
Example 2
In this example, cells in sputum samples and pleural
effusion samples derived from three patients with lung eaneer,
and cells in ascitic fluid samples derived from four patients
with gastric cancer were stained by the immunoeytochemieal
staining using KM-277. The mesothelial eells in smeared
preparations ~smear) were stained and eaneer eells in all the
preparations were not stained. Therefore, eaneer cells ean be
distinguished from mesothelial eells in smears.
